PHNONIA ROJAS: Open Payments
NPI 1417284407 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,097 in 102 payments from 24 companies in 2025. Trend: 2023 $2,042 · 2024 $2,167 · 2025 $2,097
Food & beverage: $2,097
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $531 |
| Lilly USA, LLC | 11 | $221 |
| ABBVIE INC. | 12 | $211 |
| PFIZER INC. | 9 | $142 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $141 |
| AstraZeneca Pharmaceuticals LP | 5 | $106 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $89 |
| Dexcom, Inc. | 5 | $87 |
| Merck Sharp & Dohme LLC | 3 | $70 |
Products named: Rybelsus, MOUNJARO, JARDIANCE, VRAYLAR, Wegovy, CAPLYTA, XIFAXAN, Dexcom G6 Transmitter.
Industry payments across MD — which companies pay providers there.
